When selecting a biologics CDMO, you want a partner that sets and follows realistic timelines to keep the end-to-end development and production pipeline on track. Yet sponsors often don’t know what could affect the timeline once they’ve selected a CDMO partner. All too often, this risk lies outside the CDMO itself but can be anticipated and mitigated through the right questions during evaluation, as Dr. Ralf Otto explains.
In this article, we highlight five areas where timelines can slip in a CDMO’s biologics service and the questions to ask before committing long-term, so you can gauge the likelihood of any delays.
Key Takeaways
The five timeline risks to plan for when choosing a biologics CDMO:
- Product concierge mindset (partner vs. supplier orientation)
- Raw material qualification (the most underestimated bottleneck)
- Batch release (sponsor holds final release responsibility)
- Technical flexibility and equipment readiness (adapting to program changes without losing momentum)
- Project management transparency (frequent, joint communication that catches problems early)
Timeline-Critical Aspects to Consider when Choosing a Biologics CDMO
- A Product Concierge Mindset
Delays can arise when a CDMO has a supplier mindset rather than a partner-oriented, product-focused one. Dr. Ralf Otto explains that with Rezon Bio’s ‘product concierge’ concept, they extend support to a sponsor’s other external CDMOs, helping troubleshoot technical challenges that arise elsewhere in the supply chain. For instance, Rezon Bio’s final formulation team helped troubleshoot problems experienced by an external fill-finish CDMO, keeping the program on track.
“We are not a supplier. We consider ourselves a partner. And as we have been a product company ourselves, we are product-oriented. Not all CDMOs are product-oriented.” — Dr. Ralf Otto, COO
Ask: “Have you ever helped a client resolve a problem with a different CDMO in their network? What did that look like?”
- Raw Material Qualification
In Dr. Ralf Otto’s experience, raw material qualification is the single most frequently underestimated bottleneck when partnering with a CDMO. Qualification of novel materials or new vendors can add months to a program, so the right CDMO raises this with the sponsor from the start and helps develop mitigation strategies. They can also offer to help the sponsor order at risk or leverage existing certificates.
Ask: “What is your raw-material qualification process for a program like mine, where do you see the greater risks, and how would you help mitigate them?”
- Batch Release
Batch release can become a significant source of delay, particularly for biotech or biopharma sponsors with limited in-house Chemistry, Manufacturing, and Controls (CMC) or regulatory expertise. A CDMO can only perform the manufacturer’s release; the sponsor, as the license holder, is responsible for the final release. To overcome this bottleneck, some CDMOs provide dedicated, highly experienced regulatory teams to navigate and streamline this process, facilitating timely batch release with minimal delays.
Ask: “What do you expect from us on the release side, and what support do you offer sponsors without a dedicated regulatory team?”
- Technical Flexibility and Equipment Readiness
Even with a well-defined process, development programs evolve. New equipment may need to be introduced, additional manufacturing capacity may be required, or a process may need to be transferred between production lines. A CDMO’s ability to qualify new equipment quickly, demonstrate comparability, and implement technical changes efficiently can have a significant impact on project timelines.
Sponsors should evaluate whether a CDMO’s manufacturing platform closely aligns with their process requirements and whether the organization has established procedures for introducing new technologies and equipment without creating unnecessary delays. A technically agile CDMO can adapt to evolving program needs while maintaining quality, regulatory compliance, and development momentum.
Technical fit goes beyond today’s manufacturing capabilities. Programs evolve, and your CDMO must be able to introduce new equipment, qualify new technologies, or adapt capacity when needed without creating unnecessary delays.” – Dr. Ralf Otto, COO
Ask: “How do you handle equipment changes or capacity shifts mid-program, and what’s your typical timeline for qualifying something new?”
- Project Management Transparency
Reliable product delivery relies on frequent, transparent, and joint project management alongside the sponsor. Meeting deadlines relies on the early discovery of potential issues and their efficient, transparent resolution. Without this regular CDMO-sponsor communication, deadlines could be missed.
“There must be a strong interaction between the project management teams. With Rezon Bio, they meet very regularly, maybe almost too often, but there is a transparent exchange. If something happens, we work through it together with joint troubleshooting and obstacle removal.” – Dr. Ralf Otto, COO
Ask: “How does your project management team interact with ours, and how do you handle joint troubleshooting when something slips?”
When to Engage a Biologics CDMO?
Earlier than you think. It’s never too early to engage with a CDMO. Sponsors often begin CDMO selection after a trigger event like a funding round close, Phase I readout, or internal budget approval. Yet, as Dr. Ralf Otto says, “You can negotiate nine months, and then you should have started yesterday.” CDMO onboarding has its own timeframes, so by the time the sponsor is ready to engage, the program should ideally already be in motion. In practice, a genuinely client-oriented, product-concierge CDMO has the timing-and-prerequisites conversation before contract signature, not after.
Staying Ahead of Timeline Risk
Biologics timeline risk is rarely visible until it’s already a problem. Raw material qualification, batch release responsibility, equipment changes, and the day-to-day discipline of joint project management all factor into timeline considerations when selecting a biologics CDMO. However, sponsors who ask the right questions early, understand where the real bottlenecks will likely surface, and engage their prospective CDMO partner well before they think they need to are best positioned to keep their programs on track.
Ready to build a program timeline that holds? Talk to us about how Rezon Bio plans for the risks that matter before they become delays.
Dr. Ralf Otto is Chief Operating Officer at Rezon Bio, joining in 2026 with two decades of biologics CDMO leadership. He holds a PhD in Biotechnology and began his career at Henkel before moving into CDMO operations at Boehringer Ingelheim, where he helped pioneer the company’s entry into contract manufacturing and led the transformation of a former Amgen site in the Bay Area. He later became a twice-elected Partner at McKinsey, building its global life sciences services practice, before serving as COO of Rentschler Biopharma Inc. At Rezon Bio as COO, he oversees development, cGMP manufacturing, engineering, and service competitiveness.
